These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28754333)

  • 1. Effect of allopurinol and uric acid normalization on serum lipids hyperuricemic subjects: A systematic review with meta-analysis.
    Castro VMF; Melo AC; Belo VS; Chaves VE
    Clin Biochem; 2017 Dec; 50(18):1289-1297. PubMed ID: 28754333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia.
    Takir M; Kostek O; Ozkok A; Elcioglu OC; Bakan A; Erek A; Mutlu HH; Telci O; Semerci A; Odabas AR; Afsar B; Smits G; ALanaspa M; Sharma S; Johnson RJ; Kanbay M
    J Investig Med; 2015 Dec; 63(8):924-9. PubMed ID: 26571421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
    Kanbay M; Huddam B; Azak A; Solak Y; Kadioglu GK; Kirbas I; Duranay M; Covic A; Johnson RJ
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1887-94. PubMed ID: 21784838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients.
    Pichholiya M; Yadav AK; Luhadia SK; Tahashildar J; Aseri ML
    Indian J Pharmacol; 2016; 48(5):522-525. PubMed ID: 27721537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-hyperuricemia effects of allopurinol are improved by Smilax riparia, a traditional Chinese herbal medicine.
    Wu XH; Wang CZ; Wang SQ; Mi C; He Y; Zhang J; Zhang YW; Anderson S; Yuan CS
    J Ethnopharmacol; 2015 Mar; 162():362-8. PubMed ID: 25617746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for hyperuricemia in hypertensive patients.
    Gois PH; Souza ER
    Cochrane Database Syst Rev; 2013 Jan; (1):CD008652. PubMed ID: 23440832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis.
    Qu LH; Jiang H; Chen JH
    Ann Med; 2017 Mar; 49(2):142-156. PubMed ID: 27689859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
    Ye P; Yang S; Zhang W; Lv Q; Cheng Q; Mei M; Luo T; Liu L; Chen S; Li Q
    Clin Ther; 2013 Feb; 35(2):180-9. PubMed ID: 23332451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
    De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
    Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
    Torres RJ; Puig JG
    Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study.
    Shelmadine B; Bowden RG; Wilson RL; Beavers D; Hartman J
    Anadolu Kardiyol Derg; 2009 Oct; 9(5):385-9. PubMed ID: 19819789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study.
    Rozza F; Trimarco V; Izzo R; Grassi D; Ferri C
    High Blood Press Cardiovasc Prev; 2016 Dec; 23(4):381-386. PubMed ID: 27644242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
    Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M
    Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between hyperuricemia and lipid profiles in US adults.
    Peng TC; Wang CC; Kao TW; Chan JY; Yang YH; Chang YW; Chen WL
    Biomed Res Int; 2015; 2015():127596. PubMed ID: 25629033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topiroxostat influences circulating lipid concentrations in hyperuricemic patients
.
    Tohyo S
    Int J Clin Pharmacol Ther; 2019 Nov; 57(11):567-570. PubMed ID: 31496508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.